83-Year-Old Alzheimer’s Patient Regains Speech After 5-Gram Psilocybin Dose
Updated
Updated · New Scientist · Jun 26
83-Year-Old Alzheimer’s Patient Regains Speech After 5-Gram Psilocybin Dose
3 articles · Updated · New Scientist · Jun 26
Summary
An 83-year-old woman with severe Alzheimer’s began initiating conversations about 19 hours after a 5-gram psilocybin dose, after years of speaking mostly in monosyllables.
Over the following days and weeks, clinicians and her son reported regained bladder control, better mobility, dressing herself and more spontaneous social interaction; a second 3-gram dose followed about a month later.
The Frontiers in Neuroscience case report says the disease was not reversed, but suggests psychedelics may temporarily unlock residual function by altering serotonin signaling, brain plasticity and network communication.
Albert Garcia-Romeu of Johns Hopkins questioned the paper’s validity and ethics, citing the high dose, lack of biomarker-based diagnosis and limited follow-up, while other researchers said the dramatic single case warrants careful trials.
Does a mushroom-induced 'awakening' in a dementia patient prove memories are not erased, but merely locked away waiting for a key?
If psilocybin can temporarily reverse advanced Alzheimer's, what are the profound risks of giving psychedelics to our most vulnerable seniors?
High-Dose Psilocybin and Transient Cognitive Recovery in Advanced Alzheimer’s: Promise, Peril, and Research Gaps
Overview
A recent case report described a woman with advanced Alzheimer's disease who experienced a temporary restoration of abilities after receiving supervised psilocybin-containing mushrooms, starting with a high 5-gram dose followed by 3 grams a month later. While improvements were observed, the report only covered the month after the first session and did not specify how long these effects lasted. The scientific community raised concerns about the high dosage and the lack of long-term follow-up, questioning the validity and ethics of the report. This case highlights both the potential and the significant uncertainties of using psilocybin in advanced Alzheimer's.